Bone formation in vivo is a complex phenomenon whereby recruitment and replication of mesenchymal precursors of osteoblasts, dierentiation into preosteoblasts, osteoblasts, and mature osteoblasts ultimately result in the accumulation and mineralization of the extracellular matrix. MC3T3-E1, a clonal osteoblastic cell line, was derived from mouse calvaria and undergoes an ordered and time dependent developmental sequence leading to formation of multilayered bone nodules over a 30 ± 35 day period. This developmental pattern is characterized by the replication of preosteoblasts followed by growth arrest and expression of mature osteoblastic characteristics such as matrix maturation and eventual formation of multilayered nodules with a mineralized extracellular matrix. We have found that Ets1 is expressed in proliferating preosteoblastic cells whereas Ets2 is expressed by dierentiating and mature osteoblasts. In addition, the expression of Ets1 can be induced in MC3T3-E1 and fetal rat calvaria cells by retinoic acid (RA) which is known to exert profound eects on skeletal growth and development, bone turnover, and induce speci®c cellular responses in bone cells. Thus the multiple functions of RA in bone cells are likely to be mediated in part by Ets1. Also, Ets2 transgenic mice develop multiple neurocranial, viserocranial, and cervical skeletal abnormalities. Signi®cantly, these abnormalities are similar to the skeletal anomalies found in trisomy-16 mice and in humans with Down's syndrome, wherein the dosage of Ets2 is known to be increased. These results indicate that Ets2 has an important role in skeletal development and that Ets2 overexpression in transgenics is responsible for the genesis of the same type of skeletal abnormalities that are seen in Down's syndrome. Thus the genetic programs regulated by Ets1 and Ets2 may signi®cantly aect the development and dierentiation of osteoblasts, and in fact, Ets1 has been shown to interact with thè quintessential' osteoblast transcription factor CbfA1. This review will examine in detail the role and possible targets of Ets1 and Ets2 in osteoblast dierentiation and bone formation.
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General background
Ets1, the founding member of the ets family was originally discovered as part of the avian E26 retrovirus genome Wasylyk et al., 1998) .
At present there are more than 25 distinct members of the ets gene family, recognized based on a shared and highly conserved DNA binding domain called the ETS domain. The ETS domain consists of 85 amino acids which recognize a core motif, 5'-GGA(A/T)-3' (Graves and Petersen, 1998) . The nucleotide sequences¯anking this region in¯uence the binding of a particular ets protein Hodge et al., 1996; Janknecht and Nordheim, 1993) . The ets proteins can bind to both single and dual sites, however the binding to dual sites is more stable than the interaction with single sites . The number of nucleotides separating two core ets binding sites (EBS) also seems to in¯uence the anity by which ets proteins bind to DNA. It has been shown that as the spacing between two EBS (palindromes) increases the binding activity of ets nuclear factors decreases .
Most members of the ets transcription factors have been shown to bind to DNA as monomers. However several studies indicated that the DNA binding activity of some of the ets proteins such as Ets1 can be increased or stabilized through interaction with other cellular factors and antibodies (Sato, 1998; Seth et al., 1993; Watson et al., 1997) . Core binding factor or Cbfa1 is an example of one such nuclear factor, which interacts with Ets1 and together they regulate the expression of osteopontin gene (Sato, 1998) . Cbfa1 which belongs to the runt domain family of transcription factors has been shown to be a cardinal factor in osteoblasts dierentiation (Ducy et al., 1997; Komori et al., 1997) . In mice de®cient in Cbfa1 gene, osteoblast dierentiation is completely blocked whereas chondrocyte development is less aected (Komori et al., 1997) . The role of Cbfa1 in osteoblast dierentiation and bone formation is reviewed by Ducy et al. (2000) .
The ets transcription factors, either by direct binding to DNA or through interaction with other nuclear factors, regulate the transcription of their target genes in a temporal and tissue speci®c manner (Dalton and Treisman, 1992; Graves and Petersen, 1998; Sato et al., 1998; Watson et al., 1997) . Ets1 and Ets2 play an important role in essential biological processes such as growth, transformation, apoptosis, dierentiation, and organogenesis. The role of Ets1 and Ets2 in cellular growth and transformation is elicited from in vitro and in vivo studies involving mouse ®broblast cultures. Overexpression of ets1 or ets2 can transform primary ®broblasts and induce tumours in the nude mice indicating that ets1 and ets2 both regulate cell proliferation and transformation (Seth and Papas, 1990; Seth et al., 1989; Topol et al., 1992; Bhat et al., 1990) . However, Ets1 and Ets2 seem to play opposing roles in apoptosis. While Ets1 seems to activate pro-apoptotic pathways, Ets2 seems to inhibit apoptosis (Li et al., 1999; Sevilla et al., 1999) . Ets1 and Ets2 have been implicated in the dierentiation process as shown by many in vitro cell dierentiation models. For example, the constitutive expression of ets2 in myeloblast leukemic cells induces their dierentiation to macrophages (Aperlo et al., 1996) . Ets1 has been implicated in the development of natural killer T cells as shown by Ets1 knockout mouse which lack natural killer T cells (Walunas et al., 2000) . Ets1 is one of the most highly regulated members of the ets transcription family. Biological morphogens such as retinoic acid (RA), tumour necrosis factor-alpha (TNF-a), vascular endothelial growth factor (VEGF) and tissue plasminogen activator (TPA) all can upregulate the expression of Ets1 transcription factor that further implicates the involvement of this transcription factor in the process of growth and dierentiation Gilles et al., 1996; Wang et al., 1997) .
We have found that Ets1 and Ets2 gene products are reciprocally expressed in the developing MC3T3-E1 osteoblasts where Ets1 is expressed at higher levels in preosteoblasts and Ets2 is expressed at higher levels in post-mitotic mature osteoblasts. This review article will discuss the roles of Ets1 and Ets2 in osteoblast dierentiation and bone formation.
Bone and cartilage speci®c developmental expression of Ets factors
During vertebrate development most ets genes are expressed in several dierent tissues including bone, lung, thymus, skin and the gut (Kola et al., 1993; Maroulakou et al., 1994; Seth et al., 1992) . During the embryogenesis bone development occurs in one of two ways: intramembranous ossi®cation and endochondral ossi®cation. In intramembranous ossi®cation a population of mesenchymal cells will proliferate and directly dierentiate into osteoblasts. These cells will then synthesize the bone matrix, which is most commonly seen in¯at bones. During endochondral ossi®cation however mesenchymal cells will dierentiate into prechondroblasts and subsequently to chondroblasts. The chondroblasts will generate a cartilaginous matrix, which is later replaced by woven bone and give rise to the long bones. The replacement of the cartilaginous matrix with bone features the invasion of blood vessels and condensation of mesenchymal cells around this cartilage matrix. The development of the skeletal system in mouse starts on day 12.5 ± 13 p.c. At this developmental age the condensation of mesenchyme tissue in the cranial vault can be seen. Also precartilaginous condensation at the base of the skull could be observed. By day 14 ± 14.5 p.c. a clear cartilaginous model of the long bones can be observed as well as mesenchymal condensation at sites of bone formation. By day 15 ± 15.5 p.c. many ossi®cation centres can be seen throughout the skeletal system, particularly in long bones and calvarium.
In the developing bone Ets1, Ets2 and Erg1 exhibit distinct tissue expression patterns. Other members of the ets family are either not studied or not detected in cartilage or bone. At day 14 of mouse development, Ets1 mRNA is detected in mesenchymal cells in developing limbs, tail, vertebrate and other sites where bone development occurs (Kola et al., 1993) . Interestingly Ets1 mRNA is not detected in the cartilage (Kola et al., 1993) . On the other hand, as early as day 12.5, Ets2 is expressed in the cartilage primordia in regions of vertebrae, skull, ribs and extremities where cartilage is being actively formed and later replaced with bone (Maroulakou et al., 1994) .
During the E6 stage of chick embryo development, Erg1 gene expression is associated with precartilaginous condensation and chondrogenesis which precede bone formation (Dhordain et al., 1995) . Speci®cally, Erg1 mRNA is detected in forming cartilage in vertebral bodies around the notochord, forelimb, and the mandibular arch (Dhordain et al., 1995; Iwamoto et al., 2000) .
During murine development the expression of Ets1 and Ets2 are not exclusive to bone tissue. Ets1 mRNA can be ®rst detected on day 8 of gestation in the total embryonic RNA (Kola et al., 1993) . By day 15 Ets1 transcript can be detected in a number of dierent tissues including kidney, lung, intestine, stomach, and thymus (Kola et al., 1993) . On day 16 however, there is a dramatic change in the expression of Ets1. While Ets1 mRNA can be detected at high levels in some tissues (e.g. lung), Ets1 expression is substantially reduced in other organs (e.g. stomach and intestine) (Kola et al., 1993) . Even though the expression of Ets2 transcript can be detected in similar tissues as Ets1 during mouse development, marked dierences in localisation of expression exists (Maroulakou et al., 1994) . This dierential pattern of expression is most clearly seen in the developing gut where the expression of Ets1 is limited to mesenchymal region of the gut. Ets2 on the other hand is expressed in the epithelial lining of the gut as well as the mesenchyme (Maroulakou et al., 1994) . For a detailed discussion on the expression of ets factors during the chicken and xenopus development please see the review by Remy and Baltzinger in this issue of Oncogene.
Based on the tissue speci®c expression of Ets1, Ets2 and Erg1, it's possible that these transcription factors play an important role in cartilage and bone formation in vertebrates. The involvement of the Ets2 transcription factor in the development of bone is further supported by skeletal deformities seen in the transgenic animal model. Ets2 overexpression in mice causes osteomalacia and dome-shaped skulls which are defects seen commonly in trisomy-16 mouse (down's syndrome) where the gene dosage of Ets2 is increased (Sumarsono et al., 1996) . It is therefore important to elicit the possible downstream targets of these transcription factors, which are involved in process of osteogenesis and bone development. In order to study the role of Ets1 and Ets2 in osteogenesis we have utilized the MC3T3-E1 cell culture, which is an excellent in vitro model system to study osteoblast dierentiation and mineralization.
MC3T3-E1, an in vitro model for bone development
MC3T3-E1, a cell line established from new-born mouse calvaria and selected based on high alkaline phosphatase activity at resting state (Kodama et al., 1981) . The MC3T3-E1 cells have been shown to have the capacity to dierentiate into osteoblasts and form
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A Raouf and A Seth a nodular, mineralized bone matrix in vitro, a process that resembles intramembraneous ossi®cation, see Figure 1 (Quarles et al., 1992; Sudo et al., 1983) . This in vitro osteoblast culture system is biologically relevant in that the temporal sequence of expressed genes encoding osteoblast phenotype markers follows the speci®c pattern of gene expression and cell-type distribution observed during fetal calvarial development in vivo. The process by which a nodular extracellular matrix is formed and mineralized is complex and in MC3T3-E1 cells it can be observed in three distinct phases, namely proliferation, dierentiation and mineralization (Choi et al., 1996; Quarles et al., 1992; Sudo et al., 1983) . Each of these steps includes the tightly regulated expressions of bonerelated genes and transcription factors. During the ®rst 10 days, the MC3T3-E1 cells undergo active proliferation (Quarles et al., 1992) . This period of osteoblast development features the expression of many cell cycle related or growth related genes (c-fos, c-myc and histones) as well as extracellular matrix genes such as type I collagen (Choi et al., 1996) . Days 10 ± 20 mark the second phase of the osteoblast development. At this stage the proliferation rate of preosteoblasts decreases and they undergo dierentiation to form osteoblasts (Quarles et al., 1992) . During this dierentiation stage matrix formation/maturation occurs which is marked by elevation in the expressions of extracellular matrix proteins such as type I collagen, ®bronectin, TGFb1 and osteonectin (Choi et al., 1996) . Other proteins expressed during the dierentiation phase include alkaline phosphatase and osteopontin (Quarles et al., 1992; Vary et al., 2000) . The third and the last phase in the development of osteoblasts is the mineralization of the extracellular matrix (ECM). This stage is marked by expression of proteins such as osteocalcin, bone sialoprotein, and osteopontin, which are involved in the mineralization process (Choi et al., 1996) . These temporal changes in the expression of bone related genes during the dierent stages of MC3T3-E1 development parallels those observed in vivo (Quarles et al., 1992; Sudo et al., 1983) . Therefore the MC3T3-E1 cells provide an excellent model to study the roles of transcription factors such as Ets1 and Ets2 in osteoblast dierentiation and bone formation. Recently, using Northern blot analysis and RT ± PCR, we examined the expression pro®le of dierent ets transcription factors during the dierent phases of MC3T3-E1 development. We found that Ets1 is strongly expressed during the proliferation phase whereas Ets2 is expressed at high levels during the dierentiation and mineralization phases, see Figure 2 . Elk1, Fli1, and Elf1 expressions were found to be weak and ubiquitous. However the expression of PEA3, Pu.1, Gabpa and Sap1a could not be detected . The expression patterns of Ets1 and Ets2 both in vivo and in vitro, suggests that despite their great structural homology, they play distinct roles in osteoblast development. The dierential expression of these two transcription factors suggests that they regulate dierent bone speci®c genes during the development of MC3T3-E1 cells and in this way regulate the process of osteogenesis.

Role of Ets1 in osteogenesis
The current model of bone formation suggests that the proliferation of committed mesenchymal cells is followed by their dierentiation into preosteoblasts (osteoprogenitors), and subsequently into mature osteoblast (Aubin, 1998) . This linear sequence of proliferation and dierentiation ultimately results in the deposition of a bone matrix, which is later mineralized, see Figure 3 (Aubin et al., 1995; Stein and Lian, 1993) . Using in situ hybridization we found that Ets1 transcription factor is expressed in mesenchymal cells at sites where bone development occurs (Kola et al., 1993) . Furthermore, Ets1 gene expression MC3T3-E1 cells were grown in the presence of supplements necessary to support nodule formation and total RNA was extracted on the indicated days. Northern blot analysis was carried out using probes speci®c to Ets1, Ets2 and Osteocalcin (OC) genes is induced when P19 cells are dierentiated into mesenchymal cells by retinoic acid (RA) (Kola et al., 1993) . The strong expression of Ets1 during the proliferation of MC3T3-E1 cells and the above mentioned data together suggest that Ets1 could act by regulating genes that are involved in proliferation.
Ets1 could also act as an eector of a signal transduction pathway, which aects the osteoblast function. Thyroxin, RA, and vitamin D 3 are examples of hormones and natural morphogens, which exert profound eects on bone development both in vitro and in vivo (Kurihara et al., 1986; Mulkins et al., 1983; Ohishi et al., 1994; Traianedes et al., 1993; Varga et al., 1997; Zhou et al., 1991) . All three agents are capable of inducing speci®c genotypic responses in the MC3T3-E1 osteoblasts. For example both RA and thyroxin can induce the expression of osteopontin, alkaline phosphatase, and Ets1 (Ng et al., 1988; Ohishi et al., 1994; Varga et al., 1997; Zhou et al., 1991 . RA regulates gene expression through activation of its receptors. There are two families of RA receptors RARs, and RXRs each of which has three isotypes (a, b, and g) (Leid et al., 1992; Linney, 1992) . RARs, through formation of heterodimers with RXR initiate the transcription of target gene by interacting with speci®c sequence of DNA (Pu-G-T/G-T-C-A, directly repeated 1 ± 5 bp apart) (Leid et al., 1992; Mangelsdorf et al., 1992) .
We and others have shown that except for RXRg, all RA receptors are expressed in osteoblasts (Harada et al., 1995; Nakayama et al., 1990; Raouf et al., 2000) . Therefore it is possible that the induction of these RAinducible genes is the result of either the direct interaction of RA receptors with speci®c sequences within their promoter or the eects of RA are governed indirectly through the induction of transcription factors. Recent data from our laboratory indicate that RA and thyroxin but not vitamin D3 can induce the expression of Ets1 mRNA in MC3T3-E1 cells, see Figure 4 . Interestingly, other members of the ets family are not aected by RA treatment . The analysis of Ets1 promoter revealed four consensus RA response element half sites (RAREs) located at 794, 7152, 71765, 72252 within the Ets1 promoter . These response elements are referred to as half sites because they are spaced more that ®ve base pairs. Using gel mobility shift assays we demonstrated that RARb, RARg, and RXRa are Figure 3 The presumed sequence of events involved in osteoblast dierentiation starting from a population of pluripotent stem cells (Aubin, 1998) . The osteoprogenitors refer to a population of immature and mature osteoprogenitors. Genes shown in blue represent the potential Ets1 targets and genes in red represent the potential Ets2 targets. The reference for the expression of genes are as follows: Ets1 , Collagen type I (Aubin, 1998), Egr-1 (Frick et al., 1997; McMahon et al., 1990) , PTHrP (Aubin, 1998) , Ets2 , Alkaline phosphatase (Aubin, 1998) , Osteocalcin (Aubin, 1998) , Bone sialo protein , Osteopontin (Aubin, 1998; Vary et al., 2000) , TGFb receptorII (TGFb RII) (Iseki et al., 1995; Takeuchi et al., 1995) capable of binding to RARE I (located at 794), see Figure 5 , lanes 1 ± 2 . As Figure 5 (A and B) shows, none of the other RARE half sites (II, III, IV) were capable of competing with this binding (lanes 4 ± 6). Recently we were able to demonstrate that RARg and RXRs are capable of forming a heterodimer and bind to RARE I (see Figure 6 ). Using speci®c monoclonal antibodies against RARg and polyclonal antibodies against RXRs, we observed a supershift in our gel shift assay (Figure 6 lanes 5 ± 7) . This indicates that RARg and RXRs form a heterodimer and can speci®cally bind to the Ets1 promoter, which suggests that RARg could be responsible for transactivation of the Ets1 gene by RA. RARg is expressed in MC3T3-E1 cells and its expression is increased only by a moderate amount in the presence of RA . Our Northern blot data show a 19-fold induction in Ets1 expression after treatment of MC3T3-E1 cells with RA for 48 h . Therefore involvement of RARg in upregulation of the Ets1 gene by RA explains the delayed response that we observed . Further studies are required to determine the exact mechanism by which RA regulates the expression of the Ets1 mRNA. Since Ets1 is the only member of ets family that is regulated by RA in osteoblasts, which makes Ets1 a good candidate to mediate the action of RA in osteoblasts. Karperien et al. (1997) demonstrated that the induction of PTHrP, a bone and cartilage Figure 4 Eects of RA, Thyroxin, and Vitamin D 3 on Ets1 expression in osteoblasts. MC3T3-E1 cells were treated with all trans RA (a-t-RA, 1 mM), 9-cis-RA (9-C-RA, 1 mM), Vitamin D 3 (Vit. D, 0.1 mM), thyroxin (1 mM), or control. Total RNA was extracted after two days and Northern blot analysis was used to examine the Ets1 expression. The bottom panel shows the ethidium bromide staining of the agarose gel Figure 6 RARg and RXRs form heterodimer on the most proximal RARE I half site within the Ets1 promoter. Nuclear extract form RA treated cells was allowed to form complexes with a 32 P-labelled oligo nucleotide corresponding to the most proximal RARE I half site of the Ets1 promoter. Nuclear extracts prepared from MC3T3-E1 cells treated with RA for 48 h were used as source of proteins. Speci®c monoclonal antibodies against RARs and a polyclonal antibody against RXRs were used to detect the RA receptors that bind to RARE I. As demonstrated in lanes 5 and 6 both RARg and RXRs are capable of binding to the oligo probe. When both antibodies are used a supershifted band is observed, indicating that RARg and a RXR bind to the oligo probe as a heterodimer (lane 7). These and other RAR antibodies have been kindly provided by Dr P Chambon (Institut de Genetique et de Biologie Moleculaire et Cellulaire, France) related gene, by RA in P19 cells is mediated through an ETS site and a SP1 site. Using transient transfection studies they demonstrated that Ets1 and not Ets2 is capable of activating the PTHrP promoter. Therefore PTHrP is an example of a gene whose expression is upregulated indirectly with RA through activation of Ets1 transcription factor (see Figure 7) .
Other possible targets of Ets1 include Egr-1, tenascin-C and type I procollagen (for gene expression pro®le see Figure 3 ). Egr-1 or early growth response gene-1 is a zinc ®nger transcription factor, which belongs to a family of immediate early genes . Stimulation of MC3T3-E1 cells with growth factors and hormones activates a nuclear signalling event, which results in induction of immediate early genes such as Egr-1 (Fang et al., 1995) . Previously our lab identi®ed Egr-1 as an Ets1 target gene using the dierential display technique . This complements the role of Ets1 as a growth and proliferation regulator in the MC3T3-E1 cells.
The extracellular matrix protein, tenascin-C, is another example of a bone-related gene which has been shown to be regulated by Ets1 and other members of the ets family. Tenascin-C is a glycoprotein that is secreted by osteoblasts but is absent from mineralized matrix (Mackie and Ramsey, 1996; Mackie and Tucker, 1992) . In vivo, tenascin-C is associated with mesenchymal cells undergoing osteogenesis and chondrogenesis (Mackie and Tucker, 1992) . Therefore tenascin-C is expressed in the same bone tissues as Ets1 during development. Furthermore we have shown that Ets1 is highly expressed during the early stages of MC3T3-E1 cells. Others have demonstrated that human tenascin-C promoter contains three evolutionarily conserved ets binding sites which are capable of binding to members of the ets family (Shirasaki et al., 1999) . Therefore, it is possible that, at least in osteoblasts, the expression of tenascin-C is regulated by Ets1 transcription factor.
Approximately 90% of bone matrix is made up of type I collagen. Even though collagen is present in the mature, mineralized matrix, its mRNA expression is restricted to the proliferation and dierentiation phases of MC3T3-E1 cells (Quarles et al., 1992) . Since Ets1 is expressed at its highest levels during this phase we analysed the procollagen gene promoter. Our unpublished observations show that the type I procollagen gene promoter contains multiple ets binding sites which suggest that Ets1 may regulate the expression of this gene. For a more detailed discussion please see the review by Trojanowska in this issue of Oncogene. Taken together, our data suggest that Ets1 plays a role(s) in osteoblast proliferation and development.
Role of Ets2 in osteogenesis
Even though Ets1 and Ets2 share strong homology in their structure, their regulatory roles as transcription factors are greatly dierent (Seth et al., 1994) . We found that during the development of MC3T3-E1 osteoblasts Ets1 and Ets2 peak at dierent stages, suggesting that Ets2 would have dierent target genes than Ets1 . As Ets2 expression peaks during osteoblast dierentiation and matrix maturation phases, some of the genes expressed during these stages of osteoblast development could be potential Ets2 targets. Osteopontin (OPN) is one of the major noncollagenous ECM proteins, which is secreted by osteoblasts (McKee and Nanci, 1996a, b) . We and others have shown that OPN is highly expressed during matrix maturation and mineralization phases of the MC3T3-E1 cells (McKee and Nanci, 1996a; Vary et al., 2000) . A recent report by Sato et al. (1998) suggested that Ets1 co-operates with Cbfa-1 on the OPN promoter to regulate the expression of this gene. However our published results indicate that the expression pro®le of OPN parallels that of Ets2 and not Ets1 in MC3T3-E1 cells suggesting that OPN gene expression is most likely regulated by Ets2 . Furthermore, we demonstrated that Ets2 is capable of binding to and transactivating the OPN Figure 7 Retinoic acid eects osteoblast function through alteration of gene expression. RA can exert its eects on osteoblasts either by directly activating the transcription of target genes or by activating the transcription of transcription factors such as Ets1, which can serve as a downstream eector of RA response. RA is transported into the nucleus by cellular retinoic-acid binding proteins. Tenascin-C and procollagen type I are potential targets of Ets1 whereas PTHrP is a known target of Ets1 (see text for details) promoter using gel shift and transient transfection assays .
In order to identify other ets target genes that are associated with matrix maturation and mineralization we performed serial analysis of gene expression (SAGE) with RNA extracted from dierentiating MC3T3-E1 cells grown with or without the necessary supplements (b-glycerolphosphate and vitamin C) to form a mineralized bone matrix . An excess of 2500 genes were analysed using DNA sequencing. Over 50% of the SAGE tags are novel transcripts. Eleven per cent of the tags could be associated with previously identi®ed murine genes. Following a search for the consensus ets binding sites within the promoter of the known genes that were identi®ed by SAGE or other bone-related genes, we identi®ed a number of potential ets target genes. Since Ets2 is the only member of the ets family that is expressed at high levels during the dierentiation and matrix maturation phases, it is possible that some of these matrix associated genes are speci®cally regulated by Ets2 transcription factor, see Table 1 .
The possible role of Ets2 in osteoblast dierentiation stems from the skeletal deformities seen in the transgenic mice. The Ets2 transgenic mice have abnormalities in skeletal structures that are derived from intracartilaginous ossi®cation (including vertebrae, base of skull and the face) (Sumarsono et al., 1996) . Furthermore, histological analysis revealed disordered¯at bone formation in the skull, discontinuous and uneven mineralization of the bony trabeculae. The Ets2 transgenic mice also feature thinner and hypoplastic calvaria (Sumarsono et al., 1996) . Ets2 is expressed at high levels during the dierentiation and matrix mineralization phases of MC3T3-E1 culture. In addition, several extracellular matrix (ECM) associated gene products are targets of Ets2. Some of these matrix associated genes include: bone sialoprotein, osteonectin, osteocalcin and osteopontin (Figure 8 and Table  1) .
Ets2 has been shown to be involved in the regulation of dierentiation of certain other cell types. Overexpression of Ets2 in immature myeloid cells triggers their dierentiation to macrophages (Aperlo et al., 1996) .
Conclusions and future perspectives
There is now overwhelming evidence supporting the notion that both Ets1 and Ets2 play essential roles in osteoblast dierentiation and bone development. It is therefore important to determine the signal transduction pathways, which regulate the expression of these transcription factors. Phosphorylation of transcription factors is the major link connecting the external signals to control of gene regulation in a cell. Several members of the ets family are targets of the Ras-MAPK pathway. For example the polyoma virus enhancer sequence contains a Ras responsive element (RRE), which includes adjacent binding sites for Ets1/Ets2 and AP-1. Ras, together with Ets1 and AP-1, are needed for full functional activity of this RRE (Wasylyk et al., Figure 8 The transcriptional regulatory regions of some bone related Ets2 target genes Oncogene Role of Ets1 and Ets2 in bone development A Raouf and A Seth 1998). Regulation of early growth response genes such as c-fos, which contain serum response elements (SRE) in their promoters, requires the phosphorylation of ternary-complex factors (TCF). Elk1 (a member of the ets family), Net-b, and Sap-1a form ternary complexes with the serum response factor (SRF) on the c-fos SRE. Elk1 is phosphorylated by MAP-kinase pathways, which lead to activation of JNK or ERK or p38/ RK and form a functional TCF to activate the transcription of target genes (Wasylyk et al., 1998; Yang et al., 1998) . In this way ets transcription factors function as an eector of signal transduction pathways which control important cellular functions such as dierentiation. For a comprehensive review on signal transduction and ets please see the review by JS Yordy in this issue of Oncogene. RA and thyroxin are two potent agents that exert profound eects on osteoblasts. Both RA and thyroxin are capable of inducing the expression of bone marker genes such as alkaline phosphatase and osteocalcin which suggests that these biological morphogens can regulate the function of osteoblasts and in this way aect bone development. We have demonstrated that both RA and thyroxin can induce the expression of Ets1 transcription factor. Ets1, therefore, could act as a key mediator of RA and thyroxin eects on osteoblasts. It would be interesting to examine the morphological and genetic changes induced by overexpression and antisense repression of Ets1 and Ets2 during the proliferation, dierentiation and mineralization stages of MC3T3-E1 development. Identi®cation of downstream targets of Ets1 and Ets2 may lead to discovery of new bone marker genes which could further advance our understanding of the complex steps involved in the osteogenic process. Consequently future studies could focus on determining bone speci®c targets of Ets1 and Ets2 in the context of their stage speci®c expression during osteoblast development. Study of gene expression and regulation has progressed tremendously over the past 3 years with the rapid advances in the cDNA array technology. It is now possible to survey the expression of many genes during the distinct phases of the osteoblast dierentiation. As mentioned previously, Ets1 expression dominates the Ets2 expression during the proliferation phase of osteoblast dierentiation whereas the Ets2 expression dominates that of Ets1 during the mineralization phase. The cDNA array technology can be applied to examine the expression of many known and unknown genes during MC3T3-E1 phases of osteoblast development in order to identify possible targets of Ets1 and Ets2 in osteoblasts as well as bone speci®c genes.
This will enhance our understanding of transcriptional regulation during osteogenesis and identify markers of osteoblast dierentiation that could be important to bone function and disease.
